These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2668325)

  • 1. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly.
    Wang C; Lam KS; Arceo E; Chan FL
    J Clin Endocrinol Metab; 1989 Sep; 69(3):670-7. PubMed ID: 2668325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
    Shi YF; Harris AG; Zhu XF; Deng JY
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
    McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
    Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
    Fredstorp L; Kutz K; Werner S
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly.
    Timsit J; Chanson P; Larger E; Duet M; Mosse A; Guillausseau PJ; Harris AG; Moulonguet M; Warnet A; Lubetzki J
    Acta Endocrinol (Copenh); 1987 Sep; 116(1):108-12. PubMed ID: 2889306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
    Lamberts SW; Uitterlinden P; del Pozo E
    J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
    Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
    J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly.
    James RA; White MC; Chatterjee S; Marciaj H; Kendall-Taylor P
    Eur J Clin Invest; 1992 Aug; 22(8):554-61. PubMed ID: 1425862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
    Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
    J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects.
    Fredstorp L; Harris A; Haas G; Werner S
    J Clin Endocrinol Metab; 1990 Nov; 71(5):1189-94. PubMed ID: 2229278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW; Zweens M; Verschoor L; del Pozo E
    J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose response study of the somatostatin analogue octreotide in acromegaly.
    van Liessum PA; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
    Acta Endocrinol (Copenh); 1989 Nov; 121(5):714-20. PubMed ID: 2686331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acromegaly with long acting somatostatin analogue SMS 201-995.
    Horikawa R; Takano K; Hizuka N; Asakawa K; Sukegawa I; Hirose N; Horiba N; Kasono K; Masuda A; Ohba Y
    Endocrinol Jpn; 1988 Oct; 35(5):741-51. PubMed ID: 3220051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion.
    Mehltretter G; Heinz S; Schopohl J; von Werder K; Müller OA
    Klin Wochenschr; 1991 Jan; 69(2):83-90. PubMed ID: 1902881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
    Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
    Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.